COVID-19 - January 7, 2021
AstraZeneca’s COVID-19 vaccine obtains emergency use authorization in India
AstraZeneca’s COVID-19 vaccine has been granted emergency use authorization in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunization of adults. The approval in India is an important milestone as it will enable to supply India but also a large number of countries around the world. AstraZeneca has […]
COVID-19 - January 4, 2021
AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of COVID-19 Vaccine AstraZeneca, formerly AZD1222, for the active immunisation of individuals 18 years or older. The authorisation recommends two doses administered with an interval of between four and 12 weeks. This regimen was shown in clinical trials to be safe […]
Acquisition - December 14, 2020
AstraZeneca to acquire Alexion in USD 39 billion deal
AstraZeneca and Alexion Pharmaceuticals have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive USD 60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca’s […]
COVID-19 - December 9, 2020
Interim analysis results from AstraZeneca-Oxford Phase III trials
Results of an interim analysis of the Phase III programme conducted by Oxford University with AZD1222, peer-reviewed and published in The Lancet, demonstrated that the vaccine is safe and effective at preventing symptomatic COVID-19 and that it protects against severe disease and hospitalisation. The interim analysis for efficacy was based on 11,636 participants accruing 131 symptomatic […]
Clinical Trials - December 7, 2020
AstraZeneca announces results from Calquence trial
Long-term follow-up results from the positive ACE-LY-004 Phase II trial showed patients with relapsed or refractory mantle cell lymphoma (MCL) treated with Calquence (acalabrutinib) remained progression free for a median of 22 months, with median overall survival not yet reached at three years of follow-up. The safety and tolerability profile remained consistent. At a median follow up of […]
Pharma Business - December 2, 2020
AstraZeneca’s Forxiga approved in Japan for chronic heart failure
Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving standard of care. The approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) was based on positive results from the DAPA-HF Phase III trial published in The New England Journal of Medicine. “Forxiga’s […]
